Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells.
Peroxisome proliferators are ubiquitous rodent hepatocarcinogens, known to modulate the activities of xenobiotic-metabolising enzymes such as glutathione S-transferases (GST) and mixed-function oxidase (cytochrome P-450). In addition these compounds induce pleiotropic changes in the liver of rodents even after a short-term treatment. It has been hypothesised that the enzymatic and cellular changes induced by peroxisome proliferators may alter the toxicity of other compounds activated by cytochrome P-450 and detoxified by GST isoenzymes. The effect of nafenopin-induced changes in the liver of rats on the toxicity of an anti-cancer drug cyclophosphamide was studied using cyto- and geno-toxicity parameters in the liver and bone marrow cells. The administration of cyclophosphamide (10 or 20 mg/kg bw) to the rats pre-treated with 80 mg/kg bw of nafenopin for 2 days resulted in significantly increased cytotoxic response in bone marrow cells. However, genotoxicity of cyclophosphamide was increased only in the liver of nafenopin pre-treated rats. Low level of genotoxicity in bone marrow could be accounted for potentiated cytotoxicity of cyclophosphamide. These events coincided with a significant, up to 5-fold, increase in indirect activation-detoxication index for cyclophosphamide, determined as a ratio of ECOD and GST activities, in nafenopin treated rats. This resulted from the induction of ECOD responsible for the formation of reactive metabolites of cyclophosphamide and reduced activity of GST responsible for their detoxication. In addition, mitotic activity of hepatocytes was increased in nafenopin treated rats that might also have an impact on the genotoxicity of cyclophosphamide in this organ.
Voskoboinik
I
I
Key Centre for Applied and Nutritional Toxicology, RMIT-University, Melbourne, Victoria, Australia.
Drew
R
R
Ahokas
J T
JT
D015660:7-Alkoxycoumarin O-Dealkylase / Q000378:metabolism; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002875:Chromosomes / Q000187:drug effects; D003520:Cyclophosphamide / Q000633:toxicity*; D004357:Drug Synergism; D005982:Glutathione Transferase / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D008830:Microbodies / Q000187:drug effects*; D008956:Models, Chemical; D009153:Mutagens / Q000633:toxicity*; D009255:Nafenopin / Q000494:pharmacology*; D010088:Oxidoreductases / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D000960:Hypolipidemic Agents; D009153:Mutagens; D009255:Nafenopin; D003520:Cyclophosphamide; D010088:Oxidoreductases; D015660:7-Alkoxycoumarin O-Dealkylase; C028427:palmitoyl CoA oxidase; D005982:Glutathione Transferase